Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F17%3A10373845" target="_blank" >RIV/00064203:_____/17:10373845 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1136/bmjopen-2016-014579" target="_blank" >https://doi.org/10.1136/bmjopen-2016-014579</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1136/bmjopen-2016-014579" target="_blank" >10.1136/bmjopen-2016-014579</a>
Alternative languages
Result language
angličtina
Original language name
Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry
Original language description
Objectives: Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) explored the impact of gender, risk factors and anticoagulant (AC) treatment on 1-year outcomes in patients with nonvalvular atrial fibrillation (NVAF). Design: GARFIELD-AF is a prospective noninterventional registry. Setting: Investigator sites (n= 1048) are representative of the care settings/ locations in each of the 35 countries. Participants: Patients >= 18yrs with newly diagnosed (<= 6 weeks' duration) NVAF and >= 1 investigatordetermined stroke risk factors. Main outcome measures: Event rates per 100 person-years were estimated from the Poisson model and HRs and 95% CIs calculated. Results: Of 28 624 patients (women 44.4%; men 55.6%) enrolled, there were more elderly (>= 75 years) women (46.9%) than men(30.4%).All-cause mortality rates per 100 person-years (95% CI) for women and men were 4.48 (4.12 to 4.87) and 4.04 (3.74 to 4.38), respectively, stroke/ systemic embolism (SE) (1.62 (1.41 to 1.87) and 1.17 (1.01 to 1.36)) and major bleeding (0.93 (0.78 to 1.13) and 0.79 (0.66 to 0.95)). After adjustment for baseline risk factors in treated and untreated patients, HRs (95% CI) for women (relative to men) for stroke/ SE rates were 1.3-fold higher in women (HR 1.30 (1.04 to 1.63)), and similar for major bleeding (1.13 (0.85 to 1.50)) and all-cause mortality (1.05 (0.92 to 1.19)). Antithrombotic treatment patterns in men and women were almost identical. 63.8% women and 62.9% men received AC +/- antiplatelets. Relative to no AC treatment, the reduction in stroke/ SE rates with AC treatment was greater (p= 0.01) in men (HR 0.45 (0.33 to 0.61)) than women 0.77 (0.57 to 1.03). All-cause mortality reduction with AC treatment was similar (women: 0.65 (0.54 to 0.77); men: 0.57 (0.48 to 0.68)). The risk of major bleeding when treated with AC versus no AC was 2.33 (1.41 to 3.84) in men and 1.86 (1.16 to 2.99) in women (p value= 0.53). Conclusions: Women have a higher risk of stroke/SE and the reduction in stroke/ SE events rates with AC treatment is less in women than in men.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
BMJ Open [online]
ISSN
2044-6055
e-ISSN
—
Volume of the periodical
7
Issue of the periodical within the volume
3
Country of publishing house
GB - UNITED KINGDOM
Number of pages
10
Pages from-to
—
UT code for WoS article
000398959400165
EID of the result in the Scopus database
2-s2.0-85014587482